KAYA HOLDINGS, INC.

KAYS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2017 FY2016
Revenue $7.1K $196.3K $685.4K $889.9K $1.0M $1.0M $966.4K $952.9K
Cost of Revenue $7.5K $81.3K $225.1K $279.3K $310.7K $410.3K $394.4K $553.3K
Gross Profit $-366 $114.9K $460.3K $610.6K $718.9K $604.0K $572.0K $399.6K
Gross Margin -5.1% 58.6% 67.2% 68.6% 69.8% 59.6% 59.2% 41.9%
Operating Expenses
Research & Development
SG&A Expense $605.4K $269.8K $525.9K $780.5K $720.5K $932.6K $1.3M $504.6K
Operating Income $-2.0M $-1.0M $-1.7M $-1.4M $-1.8M $-2.3M $-2.0M $-1.8M
Operating Margin -28,343.5% -521.0% -249.7% -160.7% -178.2% -223.3% -205.7% -184.2%
Interest Expense $635.8K $602.8K $579.7K $354.4K $286.4K
Pretax Income
Income Tax Expense $23.3K $93.9K $782.1K
Net Income $-2.1M $1.6M $-3.6M $9.7M $-12.3M $7.5M $-15.1M $-20.2M
Net Margin -29,168.2% 820.0% -521.8% 1,092.7% -1,194.4% 741.6% -1,561.6% -2,120.4%
EPS (Basic) $-0.07 $0.07 $-1.00 $0.00 $-0.12 $-0.20
EPS (Diluted) $-0.07 $0.01 $-0.92 $0.02 $-0.12 $-0.20
Shares Outstanding (Basic) 28.4M 22.2M 22.2M 14.7M 13.2M 176.5M 128.0M 117.1M
Shares Outstanding (Diluted) 257.7M 203.7M 22.2M 14.7M 13.2M 176.5M 128.0M 117.1M
Dividends Per Share
← Newer Page 1 of 2 Older →